Nice post! One error though. SMD is a orphan designation and has 100 patients. The reason for this is an orphan designation is eligible for special pricing and government funding. It also has the most sites conducting trials, for the reasons stated above. Moving up the dates on AMD and lowering the number of patients to 45 was a very smart move because the company will not get any special rates for these trials.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.